News headlines about Ocera Therapeutics (NASDAQ:OCRX) have been trending somewhat negative on Tuesday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocera Therapeutics earned a news impact score of -0.02 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.4805837623232 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
OCRX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Saturday, August 26th. HC Wainwright cut Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 target price on the stock. in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $1.69.
Ocera Therapeutics (OCRX) remained flat at $$1.75 during trading on Tuesday. 378,800 shares of the stock were exchanged, compared to its average volume of 1,117,197. Ocera Therapeutics has a fifty-two week low of $0.52 and a fifty-two week high of $2.95.
Ocera Therapeutics (NASDAQ:OCRX) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.24). equities analysts expect that Ocera Therapeutics will post -0.93 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Ocera Therapeutics (OCRX) Earning Somewhat Negative News Coverage, Study Finds” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/05/ocera-therapeutics-ocrx-earning-somewhat-negative-news-coverage-study-finds.html.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.